BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 23371322)

  • 1. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
    Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
    Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
    Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
    Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly expressed STAT1 contributes to the suppression of stemness properties in human paclitaxel-resistant ovarian cancer cells.
    Wang F; Zhang L; Liu J; Zhang J; Xu G
    Aging (Albany NY); 2020 Jun; 12(11):11042-11060. PubMed ID: 32516753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
    Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
    Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
    Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
    J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
    Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
    Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
    Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
    Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
    Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
    Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
    [No Abstract]   [Full Text] [Related]  

  • 9. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.
    Kang H; Jeong JY; Song JY; Kim TH; Kim G; Huh JH; Kwon AY; Jung SG; An HJ
    Mol Carcinog; 2016 Jul; 55(7):1196-209. PubMed ID: 26207830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
    Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
    Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanog-mediated stem cell properties are critical for MBNL3-associated paclitaxel resistance of ovarian cancer.
    Sun X; Diao X; Zhu X; Yin X; Cheng G
    J Biochem; 2021 Sep; 169(6):747-756. PubMed ID: 33599261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
    Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
    J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
    Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
    Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
    Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
    Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
    Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
    Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
    Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
    PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells.
    Wu Y; Tang M; Wu Y; Weng X; Yang L; Xu W; Yi W; Gao J; Bode AM; Dong Z; Cao Y
    Cell Oncol (Dordr); 2014 Feb; 37(1):53-67. PubMed ID: 24306928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.